Bone disorders affect bone strength, structure, growth, or repair and can increase the risk of pain, deformity, or fractures. Common examples include osteoporosis, which weakens bones, and osteomalacia or rickets, in which bones do not mineralize nor...
Search Bar & Filters
Found 40 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a natural history study to better understand bone and mineral disorders, including both common and rare skeletal diseases such as tumor induced osteomalacia, osteomalacia, and familial tumoral calcinosis. The study aims to provide opportunities to study bone specimens, treat patients at the NIH Clinical Center, expose trainees to these skeletal diseases, and stimulate further research in bone biology. The study does not offer experimental treatments but focuses on evaluation and care using standard approaches. Participants receive evaluations that include medical history review, physical examination, and tests such as blood and urine analysis, X-rays, bone densitometry, bone scans, CT scans, and MRI. Bone specimens for research may be collected either from surgical bone removed during medical care or through bone biopsy performed as part of evaluation. Tissue and clinical specimens from outside institutions may also be obtained to support research objectives. During the study, participants undergo medical assessments tailored to their diagnosis with clinical and research specimen collection over time. Researchers analyze genetic and biochemical data from specimens and maintain a database of participant information and samples. The study collects data for up to 10 years, allowing ongoing evaluation of outcomes and research specimen analysis to advance understanding of bone and mineral disorders.
Actively Recruiting
Researchers are studying andecaliximab in people with recent traumatic spinal cord injury who are at risk of developing bone growth where it should not be, such as in muscles, tendons, or other soft tissues. This condition is called heterotopic ossification HO. The study aims to evaluate the safety of andecaliximab, how the drug moves through the body over time, and how it affects the body in these participants. All participants will receive weekly injections of andecaliximab under the skin during their hospital stay, clinic visits, or by self-administration if discharged. The study monitors participants over a period of up to 9 weeks, with treatment continuing during hospitalization or outpatient care. This is an open-label study, meaning all participants receive the drug and there is no placebo group. Participants will be closely monitored through safety assessments from the time they consent until four weeks after the last dose. Researchers will collect data on drug levels in the body and its biological effects throughout the study period. The study includes medical evaluations, laboratory tests, and imaging as needed, with follow-up visits to track safety and treatment impact for up to 13 weeks total.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of MACI compared to arthroscopic microfracture in treating young patients aged 10 to 17 years who have symptomatic cartilage or osteochondral defects in the knee. This Phase 3, multicenter, randomized clinical trial involves 45 participants who will be assigned to one of two treatment groups MACI or microfracture. The study aims to better understand which treatment provides improved pain relief and knee function in this patient population. Participants undergo a screening arthroscopy to confirm eligibility and measure cartilage lesion size before randomization. Those assigned to the microfracture group receive the procedure during this initial arthroscopy. For participants in the MACI group, a cartilage biopsy is collected and sent to a manufacturing facility to prepare the MACI implant. The MACI treatment is then implanted via arthrotomy within 12 weeks after screening. All participants follow a postoperative rehabilitation program, with adherence monitored by the study team. Participants are followed for two years after treatment to assess outcomes, including improvements in knee pain and function using the KOOS-Child questionnaire. The study collects data at various points, including baseline and 104 weeks post-treatment. Safety and effectiveness are closely monitored throughout this period to provide detailed information on each treatments impact on knee health and patient quality of life.
Actively Recruiting
Researchers are studying men with metastatic castration-sensitive prostate cancer to see if taking oral acetate can increase the amount of a gut bacterium called Akkermansia muciniphila. The trial aims to confirm this increase compared to standard care and to assess how well patients tolerate oral acetate. The study also explores whether higher levels of this bacterium relate to better metabolic health and bone strength. This is an early phase 1 clinical trial sponsored by Western University. Participants are randomly assigned to one of two groups. One group takes an apple cider vinegar caplet daily, containing 143 mg with 36% acetic acid, for three months. The other group receives standard care without supplementation. The study includes follow-up periods lasting up to six months to monitor changes and side effects. Throughout the study, stool samples will be collected at multiple time points to measure Akkermansia muciniphila levels. Researchers will also evaluate various metabolic markers such as blood sugar, cholesterol, and insulin resistance, plus bone health indicators. Side effects and tolerability will be checked after three months. Participants are monitored over six months to assess both primary and secondary outcomes related to metabolism and bone health.
Actively Recruiting
Tumor-induced osteomalacia TIO is a rare condition caused by tumors that affect bone health. This research aims to evaluate the use of a new PETCT imaging tracer called Al18F-NOTA-LM3 to locate tumors responsible for TIO. The study compares this tracer with the commonly used 68Ga-DOTATATE to see which one better detects the tumors, including small ones that may be missed by other imaging methods. Participants will receive two different PETCT scans one using the Al18F-NOTA-LM3 tracer and another using 68Ga-DOTATATE. For the Al18F-NOTA-LM3 scan, the tracer is injected and the whole-body scan is done 60 to 120 minutes later. For the 68Ga-DOTATATE scan, the injection is followed by a scan 40 to 60 minutes afterward. Both scans aim to identify tumor locations in the same group of patients. During the study, participants will undergo these imaging procedures and be monitored for how well each tracer detects tumors. Researchers will measure the diagnostic value of the scans and compare standardized uptake values SUV of the tumors. The study period includes follow-up to six months after completion. This comprehensive evaluation helps determine which imaging method may be more useful for diagnosing TIO.
Actively Recruiting
Researchers are evaluating changes in bone mineral density BMD around knee implants in patients undergoing cemented total knee replacement surgery with two different designs posterior stabilized and posterior cruciate retaining. The study focuses on patients aged 45 and older who have severe knee pain and disability due to conditions like osteoarthritis or other joint disorders. The goal is to compare BMD changes via dual energy X-ray absorptiometry DXA at the femoral and tibial bone near the prosthesis over a two-year period, along with patient-reported outcome measures PROMs. Participants will undergo cemented total knee replacement surgery using one of two implant designs posterior stabilized total knee arthroplasty TKA or cruciate retaining TKA. They will have DXA scans at baseline, 6 months, 12 months, and 24 months to measure bone density near the implants. Alongside imaging, clinical assessments using the Knee Society Score, Western Ontario and McMaster Universities Arthritis Index, Knee Injury and Osteoarthritis Outcome Score, and the 36-Item Short Form Health Survey will be completed at the same time points to evaluate knee function and quality of life. During the study, participants will be monitored through regular follow-up visits for two years after surgery. These visits include DXA scans and questionnaires to assess bone health and knee function. The study does not involve randomization or blinding. Researchers will analyze changes in bone density at the implant interface and track patient-reported outcomes to better understand how implant design affects bone health and recovery. The entire participation period lasts 24 months with multiple scheduled assessments.
Actively Recruiting
Researchers are evaluating a new method to repair long tubular bone defects in limbs caused by trauma, tumors, and other factors. These defects significantly affect patients quality of life and are difficult to treat with current methods, which have limitations like long treatment times, high costs, and limited donor bone availability. The study aims to assess the clinical effectiveness of tissue-engineered bone made from autologous bone marrow mesenchymal stem cells combined with decalcified bone scaffolds for this purpose. The treatment uses autologous bone marrow mesenchymal stem cells, known for their strong growth and bone-forming abilities, combined with approved allogeneic decalcified bone materials to create tissue-engineered bone in the lab. This method avoids immune rejection and offers abundant material for bone reconstruction. Participants receive this tissue-engineered bone as a repair for their long bone defects in limbs. Participants will be monitored over about 360 days after surgery to assess bone healing using radiological scoring systems and observe any adverse events. Evaluations include the time it takes to bear weight on the repaired bone and pain levels. The study includes visits at screening and at 7, 90, and 360 days post-surgery to carefully track recovery and treatment outcomes.
Actively Recruiting
This research aims to collect clinical data on the safety and performance of a range of TEKNIMED bone substitute products, including CERAFORM, TRIHA, NANOGEL, and their private labels. These synthetic bone substitutes have been used for over 20 years and are designed to fill bone voids in various surgical or traumatic bone defects. The study is a global, single-arm, non-controlled, multicenter observational study that follows patients according to the local standard medical care at each site. Participants will receive bone substitutes during surgeries such as bone grafting, spinal fusion, and cage filling. These products are bioresorbable and gradually replaced by natural bone during healing. The study includes both retrospective and prospective data collection, with the retrospective group having undergone surgery since January 1, 2015, and the prospective group being considered for surgery using these bone substitutes. The aim is to assess real-life safety and performance in current clinical practice. During the study, participants will be monitored through standard medical care visits up to 24 months to evaluate successful bone repair. Researchers will assess outcomes including pain relief, bone reconstruction, patient well-being, and satisfaction. Data collection involves clinical follow-ups and observations without additional procedures beyond routine care. The study extends until September 2032, ensuring long-term safety and effectiveness data in real-world settings.
Actively Recruiting
Camptodactyly-Arthropathy-Coxa Vara-Pericarditis CACP syndrome is a rare inherited disorder caused by mutations in the PRG4 gene. It is characterized by the combination of camptodactyly bent fingers or toes, joint problems without inflammation, and deformity of the hip bone, sometimes also involving heart and lung issues. The syndrome shows variable symptoms and may be underdiagnosed due to its rarity and resemblance to juvenile arthritis. This European multicenter study aims to collect detailed clinical, genetic, and therapeutic data to better understand the diseases characteristics and progression in children diagnosed with CACP syndrome. Participants are children diagnosed with CACP syndrome confirmed by genetic testing who were diagnosed between 2005 and early 2026. The study involves regular clinical visits approximately every six months to monitor symptoms, joint function, and possible complications like pericarditis. Imaging and lab tests are done every 1 to 2 years or as needed. No specific drug treatment is available, and the study focuses on observing the disease course, treatment approaches, and genotype-phenotype relationships over a 10-year period. Throughout the study, researchers will collect epidemiological and clinical information, including disease incidence, geographic and ethnic distribution, symptom progression, and treatment outcomes. Patient disability, pain levels, and well-being will be tracked using questionnaires. The study will also document any misdiagnoses before confirmation of CACP. Monitoring adverse events related to treatments used will be included. This long-term observation will help improve understanding and management of CACP syndrome in affected children.
Actively Recruiting
Healthy Volunteer
Researchers are studying primary aldosteronism PA, a condition where the adrenal gland produces too much aldosterone, leading to high blood pressure and low potassium. The study focuses on Black individuals, including African Americans and those of Caribbean descent, to identify genetic causes of PA and understand the effects of these mutations on adrenal tumors and aldosterone production. The research also explores potential medicines to treat PA by blocking inappropriate aldosterone production. Participants include Black adults aged 18 to 70 with difficult-to-control blood pressure or diagnosed PA, as well as relatives aged 7 and older of people with PA. Those with PA or suspected PA undergo initial screening visits lasting 1 to 2 hours and, if eligible, a hospital stay for 7 to 10 days involving various tests such as blood and urine tests, scans, heart and kidney evaluations, and bone density scans. Relatives have a single visit for medical history and blood tests. Treatments, including adrenal gland removal surgery or aldosterone-blocking drugs, may be offered based on test results. During the study, participants undergo evaluations including medical history, physical exams, blood and urine tests, imaging scans, and sample collections such as a small hair sample. Follow-up visits occur 2 to 4 weeks after surgery if performed, and participants may return about one year later for repeat testing. Researchers measure genetic mutations, tumor function, aldosterone levels, and health effects on heart, kidneys, metabolism, bones, and blood clotting. The study aims to improve understanding of PAs impact and identify effective treatments for Black patients.
1-10 of 40
1